Solventum (NYSE:SOLV) Trading 7.5% Higher – Time to Buy?

Solventum Corporation (NYSE:SOLV)’s share price shot up 7.5% during mid-day trading on Tuesday . The company traded as high as $87.21 and last traded at $86.4990. Approximately 535,453 shares traded hands during mid-day trading, a decline of 62% from the average daily volume of 1,396,965 shares. The stock had previously closed at $80.47.

Analysts Set New Price Targets

Several equities analysts have recently commented on SOLV shares. Weiss Ratings upgraded shares of Solventum from a “hold (c)” rating to a “hold (c+)” rating in a research report on Friday, July 17th. UBS Group raised Solventum from a “neutral” rating to a “buy” rating and set a $95.00 price target for the company in a research note on Tuesday. BMO Capital Markets assumed coverage on shares of Solventum in a research report on Wednesday, July 8th. They issued a “market perform” rating and a $81.00 price target on the stock. Wells Fargo & Company lowered their target price on shares of Solventum from $83.00 to $70.00 and set an “equal weight” rating on the stock in a research note on Wednesday, May 6th. Finally, KeyCorp boosted their target price on shares of Solventum from $92.00 to $93.00 and gave the stock an “overweight” rating in a research report on Wednesday, May 6th. Seven equities research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $86.00.

Solventum Stock Up 6.7%

The firm’s 50 day moving average price is $77.55 and its 200-day moving average price is $74.16. The company has a current ratio of 1.07, a quick ratio of 0.75 and a debt-to-equity ratio of 0.96. The company has a market cap of $14.87 billion, a P/E ratio of 10.48, a price-to-earnings-growth ratio of 1.20 and a beta of 0.66.

Solventum (NYSE:SOLV) last posted its quarterly earnings results on Tuesday, May 5th. The company reported $1.48 earnings per share for the quarter, topping analysts’ consensus estimates of $1.35 by $0.13. Solventum had a net margin of 17.33% and a return on equity of 23.51%. The business had revenue of $2.01 billion during the quarter, compared to the consensus estimate of $1.97 billion. During the same period in the previous year, the firm posted $1.34 earnings per share. Solventum’s revenue for the quarter was down 3.0% compared to the same quarter last year. Solventum has set its FY 2026 guidance at 6.600-6.600 EPS. As a group, equities research analysts expect that Solventum Corporation will post 6.58 EPS for the current year.

Hedge Funds Weigh In On Solventum

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in SOLV. CrossGen Wealth LLC acquired a new stake in shares of Solventum in the 4th quarter valued at approximately $25,000. Measured Wealth Private Client Group LLC bought a new position in shares of Solventum during the third quarter worth $25,000. Clearstead Trust LLC grew its holdings in shares of Solventum by 61.0% in the 1st quarter. Clearstead Trust LLC now owns 396 shares of the company’s stock valued at $26,000 after buying an additional 150 shares during the period. JNBA Financial Advisors increased its position in shares of Solventum by 205.4% in the 4th quarter. JNBA Financial Advisors now owns 339 shares of the company’s stock valued at $27,000 after buying an additional 228 shares in the last quarter. Finally, CYBER HORNET ETFs LLC bought a new position in Solventum during the second quarter worth about $28,000.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.